Home
Resources
Publications
Inhibition of IL-17A in Atherosclerosis

Inhibition of IL-17A in Atherosclerosis

Xiang Cheng, Soraya Taleb, Jun Wang, Ting-Ting Tang, Jian Chen, Xing-Li Gao, Rui Yao, Jiang-Jiao Xie, Xian Yu, Ni Xia, Xin-Xin Yan, Shao-Fang Nie, Meng-Yang Liao, Yan Cheng, Ziad Mallat, Yu-Hua Liao

Atherosclerosis. 2011 Apr;215(2):471-4.

PMID: 21300351

Abstract:

Objective:
To determine the effects of interleukin (IL)-17A inhibition on experimental atherosclerosis.
Methods and results:
ApoE(-/-) mice were treated with either rat anti-mouse IL-17A, mouse anti-mouse IL-17A or isotype-matched control antibodies for 12 weeks (n=8-10 per group). Ldlr(-/-) mice were transplanted with IL-17A-deficient or wild type bone marrow (n=8 per group). Rat anti-mouse IL-17A treatment obviously reduced plaque size by 43% (p<0.01) without evidence of reduced IL-17A signaling. In contrast, mouse anti-mouse IL-17A treatment and IL-17A deficiency in bone marrow cells did not alter lesion size despite significant reduction of IL-17A production.
Conclusions:
Inhibition of IL-17A signaling does not alter lesion development in Th1-biased C57BL/6 ApoE(-/-) and Ldlr(-/-) mice with already low levels of IL-17A production. Alteration of lesion development after repeated injections of rat anti-mouse IL-17A antibody in ApoE(-/-) mice could not be attributed to blockade of IL-17A signaling.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42413365	IL-17A from rat			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: